Clinical Trials on Alzheimer’s Disease: Challenges and Opportunities
Clinical trials targeting Alzheimer’s disease face multifaceted challenges amidst promising opportunities. Challenges include patient recruitment, high attrition rates, and complex trial designs. Additionally, the disease’s heterogeneous nature poses diagnostic and treatment challenges. However, advancements in biomarkers, precision medicine, and collaborative research efforts offer opportunities for innovative trial designs and targeted therapies. Addressing these challenges while leveraging emerging opportunities is crucial for advancing Alzheimer’s disease clinical research and developing effective treatments for this devastating condition.
Discussion Lead
Dr. Benedict C. Albensi, Ph.D., BCMAS, CRQM.
- Principal Investigator, Synaptic Plasticity and Cellular Memory Dysfunction Lab, Division of Neurodegenerative Disorders St. Boniface Hospital Albrechtsen Research Centre
- Professor (External Adjunct) Department of Pharmacology & Therapeutics, College of Medicine, Faculty of Health Sciences
- Former Manitoba Dementia Research Chair
- Former Everett Endowment Fund Chair
- Currently Dr. Benedict C. Albensi is a distinguished Professor and Chair of the Department of Pharmaceutical Sciences at Nova Southeastern University, Ft. Lauderdale, Florida